好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Relapse Efficacy Endpoints for the Evaluation of Disease-Modifying Therapies in Clinical Studies of Multiple Sclerosis
MS and Related Diseases
(-)
096
Authors/Disclosures
Gilmore N. O'Neill, MD, MB, MRCPI No disclosure on file
Chris H. Polman, MD (MS Center, VU Medical Center) No disclosure on file
No disclosure on file
Ludwig Kappos, MD, FAAN (RC2NB, University Hospital Basel) Dr. Kappos has nothing to disclose.
No disclosure on file
Minhua Yang No disclosure on file
Amy Pace, ScD No disclosure on file
Michael A. Panzara, MD, MPH (Neurvati Neurosciences) Dr. Panzara has received personal compensation for serving as an employee of Neurvati Neurosciences. Dr. Panzara has received personal compensation for serving as an employee of GRIN Therapeutics. Dr. Panzara has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Wave Life Sciences. Dr. Panzara has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Athira Pharma. Dr. Panzara has stock in GRIN Therapeutics. Dr. Panzara has stock in Cadenza Bio. Dr. Panzara has stock in Athira Pharma. Dr. Panzara has stock in Wave Life Sciences. Dr. Panzara has stock in Sanofi.